Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Large cancer fingerprint screening for detection of MRD

ABSTRACT: Large cancer fingerprint screening for detection of MRD

PROVIDER: PRJNA605872 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Large cancer fingerprint screening for detection of MRD

Project description:Large cancer fingerprint screening for detection of MRD

| PRJNA605873 | ENA

MRD Screening Of Human B ALL

Project description:MRD screening in Human B-ALL: monitoring B-cell repertoires in longitudinal samples of patients.

2015-09-04 | E-ERAD-391 | biostudies-arrayexpress

Cell-free DNA 5-hydroxymethylcytosine is highly sensitive for MRD assessment in acute myeloid leukemia

Project description:Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML). However, MRD cannot be detected in many patients using current methods. We developed a highly sensitive 5-hydroxymethylcytosine (5hmC) signature in cell-free DNA by analyzing 115 AML patients and 86 controls. The 5hmC method detected MRD in 20 of 29 patients with negative MRD by multiparameter flow cytometry and 11 of 14 patients with negative MRD by molecular methods. MRD detection by the 5hmC method was significantly associated with relapse-free survival. This novel method can be used in most AML patients and may significantly impact AML patient management.

2023-12-31 | GSE237057 | GEO

Enhanced detection of MRD with cfDNA Fragmentomics.

Project description:The circulating tumor DNA (ctDNA) mutation-based approach shows limited performance in minimal residual disease (MRD) detection, especially for landmark MRD detection at an early-stage cancer after surgery. Here, we describe a cell-free DNA (cfDNA) fragmentomics-based method in MRD detection of resectable non-small cell lung cancer using whole genome sequencing, and the cfDNA-fragmentomics showed a great sensitivity in predicting prognosis.

| EGAS00001007192 | EGA

New markers for minimal residual disease detection in acute lymphoblastic leukemia

Project description:To identify new markers for minimal residual disease (MRD) detection in acute lymphoblastic leukemia (ALL), we compared genome-wide gene expression of lymphoblasts from 270 patients with newly diagnosed childhood ALL to that of normal CD19 CD10 B-cell progenitors (n=4). Expression of 30 genes differentially expressed by > 3-fold in at least 25% of cases of ALL (or 40% of ALL subtypes) was tested by flow cytometry in 200 B-lineage ALL and 61 nonleukemic BM samples, including samples containing hematogones. Of the 30 markers, 22 (CD44, BCL2, HSPB1, CD73, CD24, CD123, CD72, CD86, CD200, CD79b, CD164, CD304, CD97, CD102, CD99, CD300a, CD130, PBX1, CTNNA1, ITGB7, CD69, CD49f) were differentially expressed in up to 81.4% of ALL cases; expression of some markers was associated with the presence of genetic abnormalities. Results of MRD detection by flow cytometry with these markers correlated well with those of molecular testing (52 follow-up samples from 18 patients); sequential studies during treatment and diagnosis-relapse comparisons documented their stability. When incorporated in 6-marker combinations, the new markers afforded the detection of 1 leukemic cell among 105 BM cells. These new markers should allow MRD studies in all B-lineage ALL patients, and substantially improve their sensitivity.

2011-04-20 | GSE28497 | GEO

High dimensional association detection in large-scale genomic data

Project description:High dimensional association detection in large-scale genomic data

| PRJNA656702 | ENA

EpiPanGI Dx: A cell-free DNA methylation fingerprint for the early detection of gastrointestinal cancers

Project description:EpiPanGI Dx: A cell-free DNA methylation fingerprint for the early detection of gastrointestinal cancers

| PRJNA628686 | ENA

CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD

Project description:Patients with stage Ⅰ colorectal cancer or stage Ⅱ colon cancer usually have a good prognosis and are not recommended to receive adjuvant chemotherapy after radical surgery. With the advances in liquid biopsy technology, detection of circulating tumor DNA (ctDNA) can effectively identify early-stage cancer patients with minimal residual disease (MRD) after surgery. According to the growing number of MRD studies in solid tumor, colorectal cancer patients with ctDNA-MRD detection have a poor clinical outcome and are likely to relapse within two years. This study aims to assess the efficacy of adjuvant chemotherapy with capecitabine plus oxaliplatin (CAPEOX) compared with conventional observation in MRD-positive patients with stage I colorectal cancer and clinically low-risk stage II colon cancer.

| 6161 | ecrin-mdr-crc

Detection of Y chromosome

Project description:PCR based detection of Y-chromosome compared against results obtained by CGH microarrrays in Preimplantation Genetic Screening

2017-04-05 | GSE97386 | GEO

Large-scale production of human iPSC-derived macrophages for drug screening

Project description:Large-scale production of human iPSC-derived macrophages for drug screening

| PRJNA628531 | ENA